FIL

Filament Health is a clinical-stage biotechnology company focused on the development of natural psychedelic medicines. The company utilizes a proprietary extraction and purification platform to produce pharmaceutical-grade, standardized drug candidates derived from natural sources like psilocybin-containing mushrooms. Their lead candidate, PEX010, is currently being evaluated in multiple Phase 1 and Phase 2 clinical trials for indications including major depressive disorder and substance use disorders. Filament Health distinguishes itself by focusing on natural formulations rather than synthetic alternatives, aiming to provide safer and more effective therapeutic options for mental health conditions.